Atenolol Prophylaxis in Migraine Secondary to an Arteriovenous Malformation

Authors

  • Pedro André Kowacs MD,

    Corresponding author
    1. Neurology Division, Internal Medicine Department, Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil.
    Search for more papers by this author
  • Lineu César Werneck MD

    1. Neurology Division, Internal Medicine Department, Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil.
    Search for more papers by this author

Dr. Pedro André Kowacs, Especialidade de Neurologia, Departamento de Clínica Médica, Hospital de Clinicas da UFPR, Rua General Carneiro 181, 12 ° andar, sala 12036, CEP 80060-900, Curitiba PR, Brazil.

Abstract

The migrainous syndrome secondary to a parieto-occipital arteriovenous malformation usually presents as unilateral headache with visual aura of progressive severity. We report successful prevention by atenolol of migraine with visual aura associated with an occipital vascular malformation. Effectively preventing migraine delayed specific therapeutic measures, thereby exposing the patient to the risk of an intracranial hemorrhage. The authors consider that prophylactic therapy should not be started whenever such an association is suspected.

Ancillary